A Pilot Trial to Explore the Link Between Immunological Changes, Efficacy, Safety and Tolerability of Durvalumab (MEDI4736) Plus Tremelimumab in Chemotherapy-naïve Men With Metastatic Castration-resistant Prostate Cancer (CRPC)
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 22 Jan 2018 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
- 27 Oct 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.